Skip to content

Dexamethasone in Hospitalized Patients with Covid-19.

Why this mattered

Before this trial, Covid-19 treatment was dominated by uncertainty: clinicians were using antivirals, immunomodulators, and supportive care without clear evidence that any drug reduced mortality. The RECOVERY dexamethasone result shifted the problem from “can any treatment save hospitalized Covid-19 patients?” to “which patients benefit from suppressing the inflammatory phase of disease?” Its importance lay not only in showing a statistically robust mortality reduction, but in showing that benefit depended on disease stage and respiratory support: dexamethasone helped patients requiring oxygen or mechanical ventilation, while offering no demonstrated benefit for patients not requiring respiratory support. That distinction made Covid-19 therapeutics more biologically and clinically precise.

The paper also changed what was operationally possible during a pandemic. Dexamethasone was inexpensive, widely available, familiar to clinicians, and usable in ordinary hospitals rather than only specialized research settings. Because the trial was large, randomized, and embedded in routine care, its results could be translated into practice quickly across health systems. It provided one of the first clear examples that pandemic medicine could produce reliable, practice-changing evidence at speed, without relying on small uncontrolled series or mechanistic plausibility alone.

Subsequent Covid-19 breakthroughs built on the framework this result clarified: severe disease was not only a problem of viral replication, but also of host inflammatory injury. Later trials of immunomodulators, including agents targeting interleukin-6 signaling and Janus kinase pathways, were interpreted against the background established by dexamethasone: anti-inflammatory therapy could reduce mortality when matched to the right severity window, often in combination with corticosteroids rather than as a replacement for them. In that sense, the paper did more than identify a useful drug; it helped define the therapeutic architecture of severe Covid-19.

Abstract

BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. METHODS: In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the final results of this assessment. RESULTS: A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55). CONCLUSIONS: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936; ISRCTN number, 50189673.).

Sources